FindTrial
Sign In

A longitudinal study on the symptoms of liver cancer patients during different periods of targeted and immune therapy based on network analysis, and their predictive role on quality of life

A Study on Symptom Clusters in Liver Cancer Patients After Targeted Immunotherapy Based on Symptom Network Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117166
Enrollment
Unknown
Registered
2026-01-20
Start date
2026-01-23
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Observation group:N/A

Sponsors

The First Hospital of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed with hepatocellular carcinoma (according to the 2024 edition of the Diagnosis and Treatment Specifications for Primary Liver Cancer) and received targeted therapy; 2.Age>= 18 years old and = 6 months; 4.No cognitive impairment and normal communication; 5. Informed and agreed to enter this study.

Exclusion criteria

Exclusion criteria: 1. Suffering from other malignant tumors or other serious life-threatening diseases; 2.Those whose condition is unstable or rapidly deteriorating; 3.Those who are intolerant to targeted therapy; 4.Those who withdraw from the study or withdraw their informed consent.

Design outcomes

Primary

MeasureTime frame
Core symptoms;—

Countries

China

Contacts

Public ContactChunyan Tao

The First Hospital of Jiaxing

2331569581@qq.com+86 573 8251 9999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026